Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
The purpose of this study is to assess the immunogenicity and safety of Menactra® vaccine given as a two-dose series in infants and toddlers.
Primary Objectives:
Secondary Objectives:
Full description
Study participants will receive 2 doses on Menactra® vaccine at 3 to 6 months apart and will be monitored for safety and immunogenicity.
The planned duration of each subject's participation in the trial will be from 118 to 215 days.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
A prospective subject should not be included in the study until the condition has resolved or the febrile event has subsided.
Primary purpose
Allocation
Interventional model
Masking
300 participants in 1 patient group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal